Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients.
Angiogenesis
Angiopoietin-2
Carbon tetrachloride
Chronic hepatitis C
Endothelin-1
Liver fibrosis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
08 Feb 2021
08 Feb 2021
Historique:
received:
28
09
2020
accepted:
27
01
2021
entrez:
9
2
2021
pubmed:
10
2
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Pathological angiogenesis is involved in the development of hepatocellular carcinoma. In patients with chronic hepatitis C (CHC), the level of angiogenic factor angiopoietin (ANGP)-2 is reported to be increased in the blood, correlating with fibrosis. In this study, we aimed to clarify whether blood ANGP-2 is useful as a biomarker for liver angiogenesis and fibrosis in CHC patients and to further reveal the relationship between such pathology in a carbon tetrachloride (CCl Plasma levels of ANGP-2, expression of a liver sinusoidal endothelial cell (LSEC) marker (CD31), collagen deposition (Sirius Red staining) in the liver, clinical fibrosis markers (Mac-2 binding protein glycosylation isomer, virtual touch quantification, and liver stiffness measurement), and liver function (albumin bilirubin score) were examined in CHC patients. To determine the effects of an anti-angiogenic agent on liver fibrosis in vivo, sorafenib was administered to the CCl The plasma levels of ANGP-2 were increased in CHC patients compared to healthy volunteers and decreased by the eradication of hepatitis C with direct-acting antivirals. In addition, plasma ANGP-2 levels were correlated with CD31 expression, collagen deposition, clinical fibrosis markers, and liver function. Sorafenib inhibited liver angiogenesis and fibrosis in the CCl ANGP-2 may serve as a useful biomarker for liver angiogenesis and fibrosis in CHC patients. In addition, angiogenesis and fibrosis may be closely related.
Sections du résumé
BACKGROUND
BACKGROUND
Pathological angiogenesis is involved in the development of hepatocellular carcinoma. In patients with chronic hepatitis C (CHC), the level of angiogenic factor angiopoietin (ANGP)-2 is reported to be increased in the blood, correlating with fibrosis. In this study, we aimed to clarify whether blood ANGP-2 is useful as a biomarker for liver angiogenesis and fibrosis in CHC patients and to further reveal the relationship between such pathology in a carbon tetrachloride (CCl
METHODS
METHODS
Plasma levels of ANGP-2, expression of a liver sinusoidal endothelial cell (LSEC) marker (CD31), collagen deposition (Sirius Red staining) in the liver, clinical fibrosis markers (Mac-2 binding protein glycosylation isomer, virtual touch quantification, and liver stiffness measurement), and liver function (albumin bilirubin score) were examined in CHC patients. To determine the effects of an anti-angiogenic agent on liver fibrosis in vivo, sorafenib was administered to the CCl
RESULTS
RESULTS
The plasma levels of ANGP-2 were increased in CHC patients compared to healthy volunteers and decreased by the eradication of hepatitis C with direct-acting antivirals. In addition, plasma ANGP-2 levels were correlated with CD31 expression, collagen deposition, clinical fibrosis markers, and liver function. Sorafenib inhibited liver angiogenesis and fibrosis in the CCl
CONCLUSIONS
CONCLUSIONS
ANGP-2 may serve as a useful biomarker for liver angiogenesis and fibrosis in CHC patients. In addition, angiogenesis and fibrosis may be closely related.
Identifiants
pubmed: 33557759
doi: 10.1186/s12876-021-01633-8
pii: 10.1186/s12876-021-01633-8
pmc: PMC7871374
doi:
Substances chimiques
ANGPT2 protein, human
0
Angiopoietin-2
0
Angpt2 protein, mouse
0
Antiviral Agents
0
Carbon Tetrachloride
CL2T97X0V0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55Subventions
Organisme : National Center for Global Health and Medicine
ID : 30-shi-2001
Organisme : National Center for Global Health and Medicine
ID : 20A1002
Organisme : National Center for Global Health and Medicine
ID : 30-shi-1011
Organisme : Japan Agency for Medical Research and Development
ID : 19fk0210058h0001
Organisme : Japan Agency for Medical Research and Development
ID : 20fk0210058h0002
Références
J Hepatol. 2017 Jan;66(1):212-227
pubmed: 27423426
World J Hepatol. 2015 Mar 27;7(3):377-91
pubmed: 25848465
Hepatol Res. 2020 Jun;50(6):671-681
pubmed: 32020702
Hepatology. 2019 Feb;69(2):729-741
pubmed: 30141205
Mod Pathol. 2003 Jun;16(6):552-7
pubmed: 12808060
Biomed Pharmacother. 2017 Apr;88:459-468
pubmed: 28122312
Nat Mater. 2017 Dec;16(12):1252-1261
pubmed: 29170554
Gastroenterology. 2008 Nov;135(5):1729-38
pubmed: 18823985
Life Sci. 2014 Nov 24;118(2):156-64
pubmed: 24378671
Hepatology. 2019 Mar;69(3):1087-1104
pubmed: 30259536
J Clin Invest. 2016 Sep 1;126(9):3495-510
pubmed: 27548530
Hepatology. 2015 May;61(5):1740-6
pubmed: 25131509
Cancer Res. 2013 Mar 15;73(6):1649-57
pubmed: 23467610
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
Cancer Lett. 2016 Oct 1;380(2):525-33
pubmed: 25312939
Anticancer Res. 2013 Mar;33(3):1013-21
pubmed: 23482775
Biomedicines. 2017 Jun 21;5(2):
pubmed: 28635679
J Hepatol. 2010 Jul;53(1):132-44
pubmed: 20447716
Hepatology. 2005 Sep;42(3):696-701
pubmed: 16104024
J Hepatol. 2016 Sep;65(3):608-17
pubmed: 27151183
Hepatology. 2018 Sep;68(3):1010-1024
pubmed: 29604220
J Clin Invest. 2016 Sep 1;126(9):3511-25
pubmed: 27548529
World J Gastroenterol. 2016 Nov 28;22(44):9744-9751
pubmed: 27956798
Hepatology. 1998 Feb;27(2):472-80
pubmed: 9462646